This website is dedicated to information specific to the Maximum Fair Price (MFP) for JANUVIA only. JANUVIA is subject to the MFP under the Inflation Reduction Act beginning January 1, 2026. All valid, non-expired, saleable US NDCs of JANUVIA are included.To streamline communication regarding MFP matters, Merck is using the Beacon platform which is available through Merck’s vendor, Second Sight Solutions. The Beacon platform is a free web-based application available to all dispensing entities. Merck encourages all dispensing entities to enroll in the Beacon platform. Beacon serves as the centralized hub for Merck to share key information with dispensing entities, including Merck’s MFP effectuation plan and its associated procedures. The Beacon platform also features a resolution center designed to facilitate the receipt, response, and tracking of communications from dispensing entities regarding MFP effectuation. Dispensing entities may contact the Beacon customer support center with specific questions about the Beacon platform and may view recorded webinars that explain Beacon platform functionality and use. Following a brief registration process, dispensing entities will be verified and then have access to Beacon. The Beacon platform is available online or via email 24 hours a day, 7 days a week, with live phone and chat support available from the Vendor’s representatives Monday through Friday, 9 AM to 9 PM ET. Dispensing entities may now register at Beacon. For dispensing entities with questions: Click here to access Beacon Dispensing entities that are not 340B covered entities may also communicate with Merck regarding MFP-related matters for JANUVIA including if the dispensing entity believes a specific MFP refund transaction does not reflect appropriate access to the MFP for JANUVIA by completing the form below. Frequently Asked Questions default-sum-open-background-colordefault-sum-close-background-colorfalsedefault-sum-open-hover-colordefault-sum-open-focus-colordefault-sum-close-focus-color.default-sum-close-hover-colorHow do I dispute an unpaid MFP request for JANUVIA?Merck encourages any dispensing entity that believes a specific MFP refund transaction does not reflect appropriate access to the MFP for JANUVIA to engage in a good faith resolution. Dispensing entities are encouraged to first contact Beacon for MFP-related questions. Click here: Beacon.Additionally, entities may contact Merck by completing the form below. default-sum-open-background-colordefault-sum-close-background-colorfalsedefault-sum-open-hover-colordefault-sum-open-focus-colordefault-sum-close-focus-color.default-sum-close-hover-colorWhat process is Merck establishing for cash constrained pharmacies who are processing MFP effectuation for JANUVIA?To help mitigate potential short-term cashflow concerns related to MFP effectuation, Merck will make best efforts where feasible to expedite the MFP refund timeline for claims for all dispensing entities received from the MTF Data Module (MTF DM) during January 2026, including those that have cashflow concerns. default-sum-open-background-colordefault-sum-close-background-colorfalsedefault-sum-open-hover-colordefault-sum-open-focus-colordefault-sum-close-focus-color.default-sum-close-hover-colorWhat Merck products are involved in MFP?JANUVIA default-sum-open-background-colordefault-sum-close-background-colorfalsedefault-sum-open-hover-colordefault-sum-open-focus-colordefault-sum-close-focus-color.default-sum-close-hover-colorWhat NDCs of JANUVIA are eligible for MFP?All valid, non-expired, saleable US NDCs of JANUVIA are included. default-sum-open-background-colordefault-sum-close-background-colorfalsedefault-sum-open-hover-colordefault-sum-open-focus-colordefault-sum-close-focus-color.default-sum-close-hover-colorHow do I contact Merck for MFP questions for JANUVIA?Dispensing entities are encouraged to first contact Beacon for MFP-related questions. Click here: Beacon. Should non-340B Covered dispensing entities want to communicate directly with Merck regarding MFP-related matters for JANUVIA, including if the dispensing entity believes a specific MFP refund transaction does not reflect appropriate access to MFP for JANUVIA, complete the form below. default-sum-open-background-colordefault-sum-close-background-colorfalsedefault-sum-open-hover-colordefault-sum-open-focus-colordefault-sum-close-focus-color.default-sum-close-hover-colorHow do I contact Merck if I have questions regarding the MFP for JANUVIA?Dispensing entities are encouraged to first contact Beacon for MFP-related questions. Click here: Beacon. Should non-340B Covered dispensing entities want to communicate directly with Merck regarding MFP-related matters for JANUVIA, including if the dispensing entity believes a specific MFP refund transaction does not reflect appropriate access to MFP for JANUVIA, complete the form below. Form To Contact Merck with Questions Regarding MFP for JANUVIA "*" indicates required fields FacebookThis field is for validation purposes and should be left unchanged.Customer Name*Customer email* Customer phone numberMedicare Transaction Facilitator (MTF) Internal Claim Number (ICN)*Medicare Transaction Facilitator (MTF) XRefNDC11Select00006022128-JANUVIA 25MG TABLET 100UU 1 UNIT OF USE BOTTLE OF 10000006022131-JANUVIA 25MG TABLETS 30UU 1 UNIT OF USE BOTTLE OF 3000006022154-JANUVIA 25MG TABLETS 90UU 1 UNIT OF USE BOTTLE OF 9000006011228-JANUVIA 50MG TABLET 100UU 1 UNIT OF USE BOTTLE OF 10000006011231-JANUVIA 50MG TABLETS 30UU 1 UNIT OF USE BOTTLE OF 3000006011254-JANUVIA 50MG TABLETS 90UU 1 UNIT OF USE BOTTLE OF 9000006027728-JANUVIA 100MG TAB 100UU 1 UNIT OF USE BOTTLE OF 10000006027731-JANUVIA 100MG TABLET 30UU 1 UNIT OF USE BOTTLE OF 3000006027754-JANUVIA 100MG TABLET 90UU 1 UNIT OF USE BOTTLE OF 9000006027782-JANUVIA 100MG TAB 1000UD 1 BOTTLE OF 1000Date of service DD slash MM slash YYYY Quantity/UnitsService provider number of the pharmacy (NPI)Supporting documentationAccepted file types: pdf, jpeg, Max. file size: 25 MB. Description of the issue Δ